2024
Risk prediction for clonal cytopenia: multicenter real-world evidence
Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, DOI: 10.1182/blood.2024024756.Peer-Reviewed Original ResearchMyeloid neoplasmsIncidence of MNClonal cytopeniaCumulative incidencePlatelet count <High-risk mutationsCox proportional hazards modelsVariant allele fractionProportional hazards modelClinical trial designCCUS patientsStratify patientsGray's testC-indexDisease entityRisk groupsCytopeniasAllele fractionSomatic mutationsRisk factorsHigh riskNatural historyRisk scoreHazards modelPatientsClonal cytopenia of undetermined significance: definitions, risk and therapeutic targets
Taborda C, Zeidan A, Mendez L. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets. Frontiers In Hematology 2024, 3: 1419323. DOI: 10.3389/frhem.2024.1419323.Peer-Reviewed Original ResearchClonal hematopoiesis of indeterminate potentialClonal hematopoiesisClonal cytopeniaSomatic genetic alterationsTherapeutic targetStem/progenitor cell populationsRisk stratification toolBlood of individualsMyeloid malignanciesMyeloid neoplasmsHematologic malignanciesPotential therapeutic targetIndeterminate potentialRisk stratificationBlood countGenetic alterationsStratification toolClinical investigationNatural historyCell populationsCytopeniasMalignancyBloodRiskCytopenia(s
2023
Epidemiology and Pathogenesis of Myelodysplastic Syndrome
Rotter L, Shimony S, Ling K, Chen E, Shallis R, Zeidan A, Stahl M. Epidemiology and Pathogenesis of Myelodysplastic Syndrome. The Cancer Journal 2023, 29: 111-121. PMID: 37195766, DOI: 10.1097/ppo.0000000000000665.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeClonal hematopoiesisMDS pathophysiologyFrank MDSOutcomes of patientsOngoing clinical trialsAcute myeloid leukemiaIndividualized therapeutic approachesRisk assessment toolVariable cytopeniasOverall incidenceUnderlying pathophysiologyClinical trialsIneffective hematopoiesisMyeloid leukemiaNovel therapiesClonal cytopeniaTherapeutic modalitiesClonal disorderTherapeutic approachesUnique molecular profileEpidemiological assessmentDisease evolutionUnknown significancePathophysiologySpectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms
Xie Z, Chen E, Mendez L, Komrokji R, Zeidan A. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. The Cancer Journal 2023, 29: 130-137. PMID: 37195768, DOI: 10.1097/ppo.0000000000000656.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsClonal hematopoiesisHigh-risk patientsRisk of progressionSuch patientsUndetermined significanceAge-related diseasesHematologic malignanciesClonal cytopeniaMyeloid neoplasmsHigh riskUnmet needMyeloid malignanciesNatural historyCH managementPatientsMalignancySignificant knowledge gapsRiskHematopoiesisCytopeniasNeoplasmsSyndrome
2022
The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
Xie Z, Smith A, Komrokji R, Al Ali N, Patel A, Saygin C, Zeidan A, Bewersdorf J, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Foran J, Badar T, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg J, Ades L, Yi C, Osman A, Dinner S, Abaza Y, Chandhok N, Soong D, Taylor J, Brunner A, Carraway H, Singh A, Geyer S, Padron E, Patnaik M, Savona M, Al-Kali A. The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias. Blood 2022, 140: 2887-2890. DOI: 10.1182/blood-2022-162367.Peer-Reviewed Original Research
2021
Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study
Xie Z, Hyun M, Komrokji R, Zeidan A, Madanat Y, Zeidner J, Coombs C, Griffiths E, Lai C, Kishtagari A, Foran J, Badar T, Yi C, Desai P, Ades L, Osman A, Taylor J, Deeg H, Brunner A, Carraway H, Al Ali N, Bewersdorf J, Prebet T, Singh A, Tsai C, Chandhok N, Soong D, Patnaik M, Savona M, Al-Kali A. Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study. Blood 2021, 138: 2158. DOI: 10.1182/blood-2021-146254.Peer-Reviewed Original ResearchClinical Trials CommitteeProgression-free survivalIndependent review committeeOverall survivalTrials CommitteeDisease progressionBristol-Myers SquibbMyeloid neoplasmsResponse rateFunctional pathway analysisSpeakers bureauUndetermined significanceMultivariable modelClonal cytopeniaReview CommitteeMedian progression-free survivalBoehringer IngelheimAdvisory CommitteeMulti-centre international studyCG abnormalitiesCox proportional hazards modelGene panelDaiichi SankyoBaseline clinical dataKaplan-Meier method